Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tezepelumab for eosinophilic esophagitis
ChiCTR2500096479Phase 3Recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tezepelumab in eosinophilic esophagitis (EoE) (3 arms), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoints: Histologic response rate and Change from baseline in DSQ score. Started Jan 2025; status: recruiting.
02
Drugs
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on ChiCTR2500096479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096479.